Chief Operating Officer · Kezar Life Sciences, Inc. (KZR)

Mark Schiller

A named executive officer of Kezar Life Sciences in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$603,819

Salary $469,600Stock awards $0

FY2024: $868,378

3rd of 3 named executive officers at Kezar Life Sciences by FY2025 total.

3 named officers on file for Kezar Life Sciences, FY2025

Mark Schiller’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kezar Life Sciences’s whole pay program stands against its peers

  • Kezar Life Sciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KZR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (10-K/A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mark Schiller’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Schiller compensation by year

Kezar Life Sciences Summary Compensation Table · all 2 fiscal years held
In US dollars, as Kezar Life Sciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$451,000$469,600
Bonus$0$0
Stock awards$0$0
Option awards$230,393$120,219
Non-equity incentive$173,185$0
Pension and deferred compensation$0$0
All other$13,800$14,000
Total$868,378$603,819

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kezar Life Sciences, Inc. 10-K/A filed April 30, 2026, accession 0001628280-26-028914, and prior-year filings.

How this page was built: the Kezar Life Sciences, Inc. filed document, accession 0001628280-26-028914. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$868K
$604K
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option271—$22.80
Option4,469—$22.80
Option13,021—$9.30
Option18,885—$6.58

Per the Outstanding Equity Awards at Fiscal Year-End table in Kezar Life Sciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2025 proxy (filed April 30, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-11Disposition to the issuer derivative—11,000$0.000
2026-05-11U—2,739—0
2026-05-11Disposition to the issuer derivative—25,000$0.000
2026-05-11Disposition to the issuer derivative—24,500$0.000
2026-05-11Disposition to the issuer derivative—12,000$0.000
2026-05-11Disposition to the issuer derivative—4,999$0.000
2026-05-11Disposition to the issuer derivative—2,499$0.000
2026-05-11Disposition to the issuer derivative—5,249$0.000

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Kezar Life Sciences’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Christopher KirkChief Executive Officer$1,220,828
Marc BelskyChief Financial Officer$610,119
Mark Schiller · this pageChief Operating Officer$603,819

The full Kezar Life Sciences compensation record

free company brief

This page is one person within Kezar Life Sciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kezar Life Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Schiller's compensation dossier · One-time report. No refunds.